Trial Profile
An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Acoramidis (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Adverse reactions
- Sponsors Eidos Therapeutics
- 01 Feb 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2027.
- 01 Feb 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2027.
- 04 Apr 2022 Results (As of August 9, 2021; n=31) presented at the 71st Annual Scientific Session of the American College of Cardiology.